Signal Genetics Announces Master Service Agreement

CARLSBAD, Calif., June 30, 2015 --- Signal Genetics, Inc. (SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the signing of a Master Service Agreement (MSA) with a leading pharmaceutical company. Under the MSA, Signal's proprietary MyPRS(R) genetic test will be run across multiple clinical trials in connection with the development of novel treatments for patients with multiple myeloma.

Signal and the pharmaceutical company have triggered the first of four studies as part of the MSA. Under the agreement, MyPRS(R) will help inform patterns of response to novel therapy regimens with the aim of enabling physicians to better manage multiple myeloma patients based on their specific genetic profile.

Published: 30 June 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Signal Genetics Inc ( SGNL )

Transgenomic Announces Plans to Launch Liquid Biopsy Cancer Test Pipeline During 2015

Plans to Release Up to Six New Lab-Based Cancer Tests This Year Targeting Actionable Mutations in Melanoma, Lung Cancer and Colorectal Cancer for Use with Tissue or Liquid Biopsy Samples

Transgenomic, Inc. (TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced that it is planning to launch up to six new genetic cancer tests this year based on its Multiplexed ICE COLD-PCR™ (MX-ICP) technology. The new tests will focus on actionable genetic mutations and alterations in patients with melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer, and will include both single tests and multi-gene panels. Transgenomic’s MX-ICP technology has demonstrated exceptional sensitivity and accuracy using either standard tissue or liquid biopsy samples such as blood and plasma. The tests are expected to be available for diagnostic use through Transgenomic’s CLIA-certified laboratory.

Published: 22 June 2015
Written by Editor
Nasdaq   New Product or Order   Up on News  
Read more: Transgenomic Inc ( TBIO )

Great Basin Reports 2015 First Quarter Results

42 percent growth in customer base year-over-year, and 31 percent increase in year-over-year revenues

SALT LAKE CITY, May 14, 2015 -- Great Basin Scientific, Inc. (GBSN), a molecular diagnostic testing company, today reported earnings results for the quarter ended March 31, 2015. Revenue for the quarter was $458,730, which represented a 31 percent increase in year-over-year revenues, and Loss from Operations was $3.9 million.

First Quarter 2015 Financial Results:

Miraculins Updates Market on Regulatory Progress in China for its Scout DS(R) Diabetes Screening Device

Company's Preparations for CFDA Product Testing Submission Now Complete

WINNIPEG, MANITOBA--(May 22, 2015) - Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that it has now completed all required preparations for the submission of its Scout DS® device for product testing in compliance with Chinese Food and Drug Administration (CFDA) requirements. Product testing, which must precede clinical trials in China, relates to a series of safety and operational tests that the CFDA testing center and its engineers decide are suitable for a medical device including electrical testing, biocompatibility testing, mechanical testing, stability testing, integrity testing, and other related tests to verify the device's specified operating parameters.

Published: 22 May 2015
Written by Editor
Up on News   Project Update   TSXV  
Read more: Miraculins Inc ( MOM )

Biocept Expands Oncology Diagnostic Portfolio With Launch of c-MET Biomarker

Biocept's c-MET Test Enables Physicians and Researchers to Identify Key Biomarker From Liquid Biopsy

SAN DIEGO, May 4, 2015 -- Biocept, Inc. (BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced the launch of its c-MET amplification detection test utilizing a blood-based "liquid biopsy." This diagnostic assay has the potential to help physicians identify which patients may be receptive to certain gastric and non-small-cell lung cancer (NSCLC) treatments.

The c-MET signaling pathway has shown to be dysfunctional in a wide variety of cancers. When this is the case, c-MET stimulates cell growth, invasion and metastasis -- encouraging cells to resist timely death. Given the role of the c-MET pathway in the proliferation of cancer cells, it is a target for many cancer therapies currently in development.

Published: 04 May 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Biocept Inc ( BIOC )
  1. Great Basin Scientific Inc ( GBSN )
  2. Genetic Technologies Limited ( GENE )
  3. Great Basin Scientific Inc ( GBSN )
  4. Nymox Pharmaceutical Corporation ( NYMX )
  5. Great Basin Scientific Inc ( GBSN )